PMC7267053_01
Chest CT and pelvic MRI before etoposide chemotherapy. (A,B) Multiple nodules located in both sides of the lung; (C,D) no visible recurrence shown on the pelvic MRI.
fonc-10-00859-g0001.jpg
PMC7267053_01_fonc-10-00859-g0001.jpg
F1
A chest CT scan revealed multiple lung nodules (Figure 1); however, bone scintigraphy showed no metastasis.
Histopathology of lung metastesis. (A) Hematoxylin and eosin staining (magnification: x200); (B) immunohistochemistry for 34betaE12 (magnification: x200); (C) immunohistochemistry for CK5/6 (magnification: x200); (D) immunohistochemistry for PSA (magnification: x200).
fonc-10-00859-g0002.jpg
PMC7267053_01_fonc-10-00859-g0002.jpg
F2
Immunohistochemical analysis was negative for PSA, chromogranin A, synaptophysin, androgen receptor, thyroid transcription factor-1, CD117, CD30, and octamer-binding transcription factor-4 and positive for 34betaE12, P40, CK5/6, low molecular weight cytokeratin, and Ki67 (20%) (Figure 2).
Chest CT and pelvic MRI after 5 circles etoposide chemotherapy. (A,B) 80% decrease in size of measurable lung nodules; (C,D) no visible recurrence shown on the pelvic MRI.
fonc-10-00859-g0003.jpg
PMC7267053_01_fonc-10-00859-g0003.jpg
F3
A 9-month follow-up chest CT scan revealed a nearly 80% reduction in the size of lung nodules (Figure 3).